Onco-Innovations and GSK Collaborate to Enhance Oncology Evidence

Onco-Innovations Limited and its subsidiary, Inka Health, have embarked on a research collaboration with GlaxoSmithKline (GSK). This partnership aims to refine real-world data methodologies to enhance the applicability of oncology clinical trial results. By focusing on diverse patient populations and settings, the initiative seeks to bridge the gap between controlled trials and real-world applications.

Inka Health will leverage its machine learning and analytics expertise, working alongside GSK's epidemiology specialists. A review of transportability methodologies and evaluation frameworks are in the pipeline. The collaboration also aims to produce scientific publications involving contributors from both organizations.

This strategic initiative addresses a core challenge in oncology: applying trial findings across varied global contexts. By assessing outcome-influencing factors using real-world data, the project intends to ensure consistent and meaningful interpretations of trial evidence. Through this agreement, Onco-Innovations illustrates its commitment to advancing oncology research and integrating evidence generation with analytics.